Browse
Submit Data
Databases
API
Help

Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene Expression of human bladder cancer cell line RT112 and Gemcitabine Resistant Bladder Cancer cell line RT112-Gr

ABSTRACT: In this research, Human OneArray Microarray analysis was performed to obtain broad spectrum information about the genes differentially expressed in human bladder cancer cell line RT112 and Gemcitabine Resistant Bladder Cancer cell line RT112-Gr.

ORGANISM(S): Homo sapiens

SUBMITTER: sentai ding

PROVIDER: E-MTAB-3495 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Publications

A Potent Chemotherapeutic Strategy with Eg5 Inhibitor against Gemcitabine Resistant Bladder Cancer.

Sun Liang L Lu Jiaju J Niu Zhihong Z Ding Kejia K Bi Dongbin D Liu Shuai S Li Jiamei J Wu Fei F Zhang Hui H Zhao Zuohui Z Ding Sentai S

PloS one 20151210 12

Development of resistance to gemcitabine is a major concern in bladder cancer therapy, and the mechanism remains unclear. Eg5 has been recently identified as an attractive target in cancer chemotherapy, so novel targeted chemotherapy with Eg5 inhibitor is expected to improve the anticancer effect in gemcitabine-resistant bladder cancer. In this research, RT112-Gr cells were 350-fold less sensitive to gemcitabine than the parental cell lines, while KU7-Gr cells were 15-fold less sensitive to gemc ...[more]

PMID: 26658059

Similar Datasets

Determine the effects on the transcriptome of depleting STAG2 in RT112, a bladder cancer cell line.

Project description:Determine the effects on the transcriptome of depleting STAG2 in RT112, a bladder cancer cell line.

2020-07-23 | GSE154878 | GEO

Chromatin Profiling of L1207 bladder cancer cell line

Project description:Tumor progression is related to both genetic and epigenetic alterations. Until relatively recently, epigenetic changes were thought to target single genes only but we show that in Bladder tumours, epigenetic changes can affect whole chromosomal regions, resulting in the silencing of all the genes within those regions. This phenomenon is probably very general, and has been described in bladder, colon, breast and prostate cancers. In order to investigate epigenetic landscape and potential alterations in bladder, we established the chromatin profiling of RT112 cell line by ChIPseq for the following marks : H3K4me3, H3K9ac, H3K27me3, H3K9me3, H3K27ac, H3K4me1, and CTCF.

2023-03-22 | GSE140891 | GEO

Chromatin Profiling of RT112 bladder cancer cell line

2023-03-22 | GSE104804 | GEO

Bladder cancer lncRNA expression profiling

Project description:Using the highly sensitive lncRNA array, we screened the lncRNAs abundant in the human bladder cancer and Adjacent normal bladder tissues, and the function of differentially expressed lncRNAs were analyzed by bioinformatics. The Arraystar Human lncRNA Array (8x15K, Arraystar) and whole human mRNA Array (4x44K, Arraystar) and was used to profile differentially expressed lncRNAs and genes in bladder cancer vs. normal tissues following the manufacturerâs instructions. Briefly, extracted RNA template (1mg) was reversely transcribed into cDNA and digested into fragments with endonucleases. These fragments were labeled with DNA labeling reagent and labeled cDNAs were hybridized to the microarray via incubation at 45Â°C and rotated at 60 rpm for 17 h. Following washing and staining, the arrays were scanned using a GeneChip Scanner3000 with GeneChip Operating Software.

2016-07-02 | E-GEOD-83955 | biostudies-arrayexpress

Epigenomic mapping identifies a super-enhancer repertoire that regulates cell identity in bladder cancers through distinct transcription factor networks [siFOXA1]

Project description:RNA-seq Series of bladder carcinoma cell lines RT112 and SCaBER treated by siFOXA1.

2023-03-24 | GSE196579 | GEO

Epigenomic mapping identifies a super-enhancer repertoire that regulates cell identity in bladder cancers through distinct transcription factor networks [siZBED2_siFOXA1]

Project description:RNA-seq Series of bladder carcinoma cell lines RT112 and SCaBER treated by siZBED2 and FOXA1.

2023-03-24 | GSE196594 | GEO

Epigenomic mapping identifies a super-enhancer repertoire that regulates cell identity in bladder cancers through distinct transcription factor networks [CrispR_FOXA1]

Project description:RNA-seq Series of Bladder carcinoma cell lines RT112 and SD48 mutated for FOXA1 by CrispR.

2023-03-24 | GSE196593 | GEO

Hypermethylation of CpG Islands and Shores adjacent to mirtron and microRNA genes in bladder cancer

Project description:We examined mirtron and miR expression in bladder cancer cell line following DNA Methyltransferase inhibition and normal urothelium using human Agilent microRNA microarrays. Bladder cancer cell lines (EJ, RT4 and RT112) were treated with 5-azacytidine ''Aza'' (2uM) for 5-7 days and normal urothelium (NHU) were subjected for microRNA microarray analysis. Analysis were performed in triplicates or more.

2011-02-17 | E-GEOD-22380 | biostudies-arrayexpress

FGFR3-shRNA induced transcriptional changes in RT112 bladder cancer cells

Project description:Aberrant activation of FGFR3 via overexpression or mutation is a frequent feature of bladder cancer; however, its molecular and cellular consequences and functional relevance to carcinogenesis are not well understood. In this study with a bladder carcinoma cell line expressing inducible FGFR3 shRNAs, we sought to identiy transcriptional targets of FGFR3 and investigate their contribution to bladder cancer development. Bladder cancer cell line RT112 was transduced with a doxycycline-inducible control EGFP shRNA or three independent FGFR3 shRNAs, designated FGFR3 shRNA 2-4, FGFR3 shRNA 4-1 and FGFR3 shRNA 6-16. These four cell lines were treated with or without doxycycline for 48 hr to deplete FGFR3 protein prior to the isolation of mRNA for microarray analysis. Genes that were differentially expressed after doxycycline induction in all three FGFR3-depleted cell lines but not in the control cell line were considered potential FGFR3-regulated genes. Each treatment group was run in triplcates, and there are 24 samples.

2012-11-07 | E-GEOD-41035 | biostudies-arrayexpress

STAG2 loss-of-function affects short-range genomic contacts and modulates urothelial differentiation in bladder cancer cells

Project description:Cohesin exists in two variants, containing either STAG1 or STAG2. STAG2 is one of the most commonly mutated genes in human cancer, and a major bladder cancer tumor suppressor. Little is known about how its inactivation contributes to tumor development. Here, we analyze the genomic distribution of STAG1 and STAG2 and perform STAG2 loss-of-function experiments using RT112 bladder cancer cells; we then analyze the resulting genomic effects by integrating gene expression and chromatin interaction data.

2020-07-30 | GSE155380 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data